Artelo Biosciences
ARTL
8 hedge funds and large institutions have $338K invested in Artelo Biosciences in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.04% less ownership
Funds ownership: 0.26% → 0.23% (-0.04%)
11% less funds holding
Funds holding: 9 → 8 (-1)
27% less capital invested
Capital invested by funds: $464K → $338K (-$126K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.6K |
| 2 |
Two Sigma Advisers
New York
|
+$2.61K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$37K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.66K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$104 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $181K | -$24.6K | -471 | -12% |
|
|
2
Two Sigma Advisers
New York
| $104K | +$2.61K | +50 | +3% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $39K | +$3.6K | +69 | +10% |
|
|
4
UBS Group
Zurich,
Switzerland
| $8.82K | -$2.66K | -51 | -23% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $5K | +$1.09K | +21 | +30% |
|
|
CFD
6
Creative Financial Designs
Kokomo,
Indiana
| $208 | – | – | – |
|
7
Morgan Stanley
New York
| $72 | – | – | – |
|
|
8
Wells Fargo
San Francisco,
California
| $52 | -$104 | -2 | -67% |
|
|
9
Two Sigma Investments
New York
| – | -$37K | -589 | Closed |
|
ARTL Hedge Fund Activity: Q4 2022 in Review
8 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2022, worth a combined $338K — down 27% from $464K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $3.6K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $37K sold.
- 8 institutional investors held Artelo Biosciences (ARTL) as of Q4 2022, down from 9 in Q3 2022.
- Funds reported $338K of Artelo Biosciences stock for Q4 2022, down 27% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest Artelo Biosciences buyer in Q4 2022 was Geode Capital Management, an estimated $3.6K added.
- The largest Artelo Biosciences seller in Q4 2022 was Two Sigma Investments, an estimated $37K sold.
Based on aggregated 13F filings for Q4 2022.